Home TRANG CHỦ Thứ 6, ngày 26/04/2024
    Hỏi đáp   Diễn đàn   Sơ đồ site     Liên hệ     English
IMPE-QN
Web Sites & Commerce Giới thiệu
Web Sites & Commerce Tin tức - Sự kiện
Web Sites & Commerce Hoạt động hợp tác
Web Sites & Commerce Hoạt động đào tạo
Web Sites & Commerce Chuyên đề
Web Sites & Commerce Tư vấn sức khỏe
Web Sites & Commerce Tạp chí-Ấn phẩm
Finance & Retail Thư viện điện tử
Công trình nghiên cứu về Ký sinh trùng
Công trình nghiên cứu về Sốt rét & SXH
Công trình nghiên cứu về Côn trùng & véc tơ truyền
Đề tài NCKH đã nghiệm thu
Thông tin-Tư liệu NCKH
Web Sites & Commerce Hoạt động Đảng & Đoàn thể
Web Sites & Commerce Bạn trẻ
Web Sites & Commerce Văn bản pháp quy
Số liệu thống kê
Web Sites & Commerce An toàn thực phẩm & hóa chất
Web Sites & Commerce Thầy thuốc và Danh nhân
Web Sites & Commerce Ngành Y-Vinh dự và trách nhiệm
Web Sites & Commerce Trung tâm dịch vụ
Web Sites & Commerce Thông báo-Công khai
Web Sites & Commerce Góc thư giản

Tìm kiếm

Đăng nhập
Tên truy cập
Mật khẩu

WEBLINKS
Website liên kết khác
 
 
Số lượt truy cập:
5 2 5 4 3 2 3 9
Số người đang truy cập
2 2 8
 Thư viện điện tử Công trình nghiên cứu về Sốt rét & SXH
Phần 1: Một số ấn bản mới nhất về nghiên cứu kháng thuốc sốt rét trên thế giới(Tháng 1_2013)

1. A framework for assessing the risk of resistance for anti-malarials in development.

Ding XC, Ubben D, Wells TN.

Malar J. 2012 Aug 22;11:292. doi: 10.1186/1475-2875-11-292.

PMID: 22913649 [PubMed - in process]

2. Natural products as starting points for future anti-malarial therapies: going back to our roots?

Wells TN.

Malar J. 2011 Mar 15;10 Suppl 1:S3. doi: 10.1186/1475-2875-10-S1-S3.

PMID: 21411014 [PubMed - in process]

3. Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance.

White NJ, Pongtavornpinyo W, Maude RJ, Saralamba S, Aguas R, Stepniewska K, Lee SJ, Dondorp AM, White LJ, Day NP.

Malar J. 2009 Nov 11;8:253. doi: 10.1186/1475-2875-8-253.

PMID: 19906307 [PubMed - indexed for MEDLINE]

4. Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum.

Parquet V, Henry M, Wurtz N, Dormoi J, Briolant S, Gil M, Baret E, Amalvict R, Rogier C, Pradines B.

Malar J. 2010 May 25;9:139. doi: 10.1186/1475-2875-9-139.

PMID: 20497586 [PubMed - indexed for MEDLINE]

5. Detection of high levels of mutations involved in anti-malarial drug resistance in Plasmodium falciparum and Plasmodium vivax at a rural hospital in southern Ethiopia.

Mula P, Fernández-Martínez A, de Lucio A, Ramos JM, Reyes F, González V, Benito A, Berzosa P.

Malar J. 2011 Aug 2;10:214. doi: 10.1186/1475-2875-10-214.

PMID: 21810256 [PubMed - indexed for MEDLINE]

6. [Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID: 17240921 [PubMed - indexed for MEDLINE]

7. Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty.

Smith DL, Klein EY, McKenzie FE, Laxminarayan R.

Malar J. 2010 Jul 23;9:217. doi: 10.1186/1475-2875-9-217.

PMID: 20653960 [PubMed - indexed for MEDLINE]

8. Development of a TaqMan Allelic Discrimination assay for detection of single nucleotides polymorphisms associated with anti-malarial drug resistance.

Kamau E, Alemayehu S, Feghali KC, Tolbert LS, Ogutu B, Ockenhouse CF.

Malar J. 2012 Jan 20;11:23. doi: 10.1186/1475-2875-11-23.

PMID: 22264294 [PubMed - indexed for MEDLINE]

9. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.

Lu H, Tonge PJ.

Acc Chem Res. 2008 Jan;41(1):11-20. doi: 10.1021/ar700156e. Review.

PMID: 18193820 [PubMed - indexed for MEDLINE]

Related citations

10. Markers of anti-malarial drug resistance in Plasmodium falciparum isolates from Swaziland: identification of pfmdr1-86F in natural parasite isolates.

Dlamini SV, Beshir K, Sutherland CJ.

Malar J. 2010 Mar 3;9:68. doi: 10.1186/1475-2875-9-68.

PMID: 20199676 [PubMed - indexed for MEDLINE]

11. Drug resistance in Plasmodium: natural products in the fight against malaria.

Turschner S, Efferth T.

Mini Rev Med Chem. 2009 Feb;9(2):206-2124. Review.

PMID: 19200025 [PubMed - indexed for MEDLINE]

12. Antiplasmodial potential of medicinal plant extracts from Malaiyur and Javadhu hills of South India.

Kamaraj C, Kaushik NK, Mohanakrishnan D, Elango G, Bagavan A, Zahir AA, Rahuman AA, Sahal D.

Parasitol Res. 2012 Aug;111(2):703-15. doi: 10.1007/s00436-011-2457-6. Epub 2011 Jun 4.

PMID: 21643655 [PubMed - indexed for MEDLINE]

13. Case management of malaria fever in Cambodia: results from national anti-malarial outlet and household surveys.

Littrell M, Gatakaa H, Phok S, Allen H, Yeung S, Chuor CM, Dysoley L, Socheat D, Spiers A, White C, Shewchuk T, Chavasse D, O'Connell KA.

Malar J. 2011 Oct 31;10:328. doi: 10.1186/1475-2875-10-328.

PMID: 22039922 [PubMed - indexed for MEDLINE]

14. Activity of clinically relevant antimalarial drugs o­n Plasmodium falciparum mature gametocytes in an ATP bioluminescence "transmission blocking" assay.

Lelièvre J, Almela MJ, Lozano S, Miguel C, Franco V, Leroy D, Herreros E.

PLoS o­ne. 2012;7(4):e35019. doi: 10.1371/journal.pone.0035019. Epub 2012 Apr 13.

PMID: 22514702 [PubMed - indexed for MEDLINE]

15. The A/T-specific DNA alkylating agent adozelesin inhibits Plasmodium falciparum growth in vitro and protects mice against Plasmodium chabaudi adami infection.

Yanow SK, Purcell LA, Spithill TW.

Mol Biochem Parasitol. 2006 Jul;148(1):52-9. Epub 2006 Mar 23.

PMID: 16597469 [PubMed - indexed for MEDLINE]

16. The detection and treatment of Plasmodium falciparum malaria: time for change.

Nosten F, Ashley E.

J Postgrad Med. 2004 Jan-Mar;50(1):35-9.

PMID: 15047997

[PubMed - indexed for MEDLINE]

17. New medicines to improve control and contribute to the eradication of malaria.

Wells TN, Alonso PL, Gutteridge WE.

Nat Rev Drug Discov. 2009 Nov;8(11):879-91. doi: 10.1038/nrd2972. Epub 2009 Oct 16. Review.

PMID: 19834482 [PubMed - indexed for MEDLINE]

18. Spread of anti-malarial drug resistance: mathematical model with implications for ACT drug policies.

Pongtavornpinyo W, Yeung S, Hastings IM, Dondorp AM, Day NP, White NJ.

Malar J. 2008 Nov 2;7:229. doi: 10.1186/1475-2875-7-229.

PMID: 18976503 [PubMed - indexed for MEDLINE]

19. Molecular targets for design of novel inhibitors to circumvent aminoglycoside resistance.

Jana S, Deb JK.

Curr Drug Targets. 2005 May;6(3):353-61. Review.

PMID: 15857293 [PubMed - indexed for MEDLINE]

20. [Mechanisms and dynamics of drug resistance in Plasmodium falciparum].

Le Bras J.

Bull Soc Pathol Exot. 1999 Sep-Oct;92(4):236-41. Review. French.

PMID: 10572658 [PubMed - indexed for MEDLINE]

21. Evolutionary patterning: a novel approach to the identification of potential drug target sites in Plasmodium falciparum.

Durand PM, Naidoo K, Coetzer TL.

PLoS o­ne. 2008;3(11):e3685. doi: 10.1371/journal.pone.0003685. Epub 2008 Nov 10.

PMID: 18997863 [PubMed - indexed for MEDLINE]

22. The chemotherapy of rodent malaria. LXI. Drug combinations to impede the selection of drug resistance, part 4: the potential role of 8-aminoquinolines.

Peters W, Stewart LB, Robinson BL.

Ann Trop Med Parasitol. 2003 Apr;97(3):221-36.

PMID: 12803854 [PubMed - indexed for MEDLINE]

23. Use of high-density tiling microarrays to identify mutations globally and elucidate mechanisms of drug resistance in Plasmodium falciparum.

Dharia NV, Sidhu AB, Cassera MB, Westenberger SJ, Bopp SE, Eastman RT, Plouffe D, Batalov S, Park DJ, Volkman SK, Wirth DF, Zhou Y, Fidock DA, Winzeler EA.

Genome Biol. 2009 Feb 13;10(2):R21. doi: 10.1186/gb-2009-10-2-r21.

PMID: 19216790 [PubMed - indexed for MEDLINE]

24. [Frontier of mycobacterium research--host vs. mycobacterium].

Okada M, Shirakawa T.

Kekkaku. 2005 Sep;80(9):613-29. Japanese.

PMID: 16245793 [PubMed - indexed for MEDLINE]

25. Structure-based approaches to the development of novel anti-malarials.

Brady RL, Cameron A.

Curr Drug Targets. 2004 Feb;5(2):137-49. Review.

PMID: 15011947 [PubMed - indexed for MEDLINE]

26. [Prospects for development of new antituberculous drugs].

Tomioka H. Kekkaku. 2002 Aug;77(8):573-84. Japanese.

PMID: 12235850 [PubMed - indexed for MEDLINE]

27. Discovery of potent, novel, non-toxic anti-malarial compounds via quantum modelling, virtual screening and in vitro experimental validation.

Sullivan DJ Jr, Kaludov N, Martinov MN.

Malar J. 2011 Sep 20;10:274. doi: 10.1186/1475-2875-10-274.

PMID: 21933377 [PubMed - indexed for MEDLINE]

28. Antisense oligonucleotides targeting malarial aldolase inhibit the asexual erythrocytic stages of Plasmodium falciparum.

Wanidworanun C, Nagel RL, Shear HL.

Mol Biochem Parasitol. 1999 Jul 30;102(1):91-101.

PMID:10477179 [PubMed - indexed for MEDLINE]

29. High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.

Baldwin J, Michnoff CH, Malmquist NA, White J, Roth MG, Rathod PK, Phillips MA.

J Biol Chem. 2005 Jun 10;280(23):21847-53. Epub 2005 Mar 28. Erratum in: J Biol Chem. 2005 Sep 9;280(36):32048.

PMID: 15795226 [PubMed - indexed for MEDLINE]

30. Epidemiological models for the spread of anti-malarial resistance.

Koella JC, Antia R.

Malar J. 2003 Feb 19;2:3. Epub 2003 Feb 19.

PMID: 12643812 [PubMed - indexed for MEDLINE]

31. The mechanisms of resistance to antimalarial drugs in Plasmodium falciparum.

Le Bras J, Durand R.

Fundam Clin Pharmacol. 2003 Apr;17(2):147-53. Review.

PMID: 12667224 [PubMed - indexed for MEDLINE]

32. Changing pattern of antimalarial drug resistance.

Peters W.

J R Soc Med. 1989;82 Suppl 17:14-7. Review.

PMID: 2693718 [PubMed - indexed for MEDLINE]

33. The challenge of multidrug resistance: actual strategies in the development of novel antibacterials.

Schmidt FR.

Appl Microbiol Biotechnol. 2004 Jan;63(4):335-43. Epub 2003 Jun 12. Review.

PMID:12802526 [PubMed - indexed for MEDLINE]

34. Alternative strategies in drug development: clinical pharmacological aspects.

Kuhlmann J.

Int J Clin Pharmacol Ther. 1999 Dec;37(12):575-83. Review.

PMID: 10599949 [PubMed - indexed for MEDLINE]

35. Plasmodium falciparum neutral aminopeptidases: new targets for anti-malarials.

Skinner-Adams TS, Stack CM, Trenholme KR, Brown CL, Grembecka J, Lowther J, Mucha A, Drag M, Kafarski P, McGowan S, Whisstock JC, Gardiner DL, Dalton JP.

Trends Biochem Sci. 2010 Jan;35(1):53-61. doi: 10.1016/j.tibs.2009.08.004. Epub 2009 Sep 30. Review.

PMID: 19796954 [PubMed - indexed for MEDLINE]

36.Use of RDTs to improve malaria diagnosis and fever case management at primary health care facilities in Uganda.

Kyabayinze DJ, Asiimwe C, Nakanjako D, Nabakooza J, Counihan H, Tibenderana JK.

Malar J. 2010 Jul 12;9:200. doi: 10.1186/1475-2875-9-200.

PMID: 20624312 [PubMed - indexed for MEDLINE]

37. Monitoring for Plasmodium falciparum drug resistance to artemisinin and artesunate in Binh Phuoc Province, Vietnam: 1998-2009.

Thanh NV, Toan TQ, Cowman AF, Casey GJ, Phuc BQ, Tien NT, Hung NM, Biggs BA.

Malar J. 2010 Jun 24;9:181. doi: 10.1186/1475-2875-9-181.

PMID: 20573274 [PubMed - indexed for MEDLINE]

38. Review of pyronaridine anti-malarial properties and product characteristics.

Croft SL, Duparc S, Arbe-Barnes SJ, Craft JC, Shin CS, Fleckenstein L, Borghini-Fuhrer I, Rim HJ.

Malar J. 2012 Aug 9;11:270. doi: 10.1186/1475-2875-11-270.

PMID: 22877082 [PubMed - in process]

39. Study of the impact of HIV genotypic drug resistance testing o­n therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID: 11813503 [PubMed - indexed for MEDLINE]

40. Double-drug development against antioxidant enzymes from Plasmodium falciparum.

Biot C, Dessolin J, Grellier P, Davioud-Charvet E.

Redox Rep. 2003;8 (5):280-3.

PMID:14962365 [PubMed - indexed for MEDLINE]

41. Modelling the development of resistance of Plasmodium falciparum to anti-malarial drugs.

Cross AP, Singer B.

Trans R Soc Trop Med Hyg. 1991 May-Jun;85(3):349-55.

PMID:1683034 [PubMed - indexed for MEDLINE]

42.Cancer Drug Development: New Targets for Cancer Treatment.

Curt GA.

Oncologist. 1996;1(3):II-III.

PMID:10387987 [PubMed - as supplied by publisher]

43. [Combined antimalarial therapy using artemisinin].

Majori G.

Parassitologia. 2004 Jun;46(1-2):85-7. Review. Italian.

PMID: 15305693 [PubMed - indexed for MEDLINE]

44. Selection of drug resistant mutants from random library of Plasmodium falciparum dihydrofolate reductase in Plasmodium berghei model.

Tipsuwan W, Srichairatanakool S, Kamchonwongpaisan S, Yuthavong Y, Uthaipibull C.

Malar J. 2011 May 10;10:119. doi: 10.1186/1475-2875-10-119.

PMID: 21554743 [PubMed - indexed for MEDLINE]

45. The dynamics of mutations associated with anti-malarial drug resistance in Plasmodium falciparum.

Escalante AA, Smith DL, Kim Y.

Trends Parasitol. 2009 Dec;25(12):557-63. doi: 10.1016/j.pt.2009.09.008. Epub 2009 Oct 26. Review.

PMID:19864183 [PubMed - indexed for MEDLINE]

46. Anti-malarial prescriptions in three health care facilities after the emergence of chloroquine resistance in Niakhar, Senegal (1992-2004).

Munier A, Diallo A, Cot M, Ndiaye O, Arduin P, Chippaux JP.

Malar J. 2009 Apr 27;8:83. doi: 10.1186/1475-2875-8-83.

PMID: 19397797 [PubMed - indexed for MEDLINE]

47. [Malaria prevention today and tomorrow].

Félix H, Danis M.

Bull Soc Pathol Exot Filiales. 1987;80(3 Pt 2):581-92. French.

PMID: 3319265 [PubMed - indexed for MEDLINE]

48. A model for transmission of partial resistance to anti-malarial drugs.

Tasman H, Soewono E, Sidarto KA, Syafruddin D, Rogers WO.

Math Biosci Eng. 2009 Jul;6(3):649-61.

PMID: 19566133 [PubMed - indexed for MEDLINE]

49. pfcrt is more than the Plasmodium falciparum chloroquine resistance gene: a functional and evolutionary perspective.

Cooper RA, Hartwig CL, Ferdig MT.

Acta Trop. 2005 Jun;94(3):170-80. Review.

PMID: 15866507 [PubMed - indexed for MEDLINE]

50. New antimicrobial agents for the treatment of bacterial infections in cancer patients.

Rolston KV.

Hematol o­ncol. 2009 Sep;27(3):107-14. doi: 10.1002/hon.898. Review.

PMID:19569253 [PubMed - indexed for MEDLINE]

51. Molecular monitoring of Plasmodium falciparum drug susceptibility at the time of the introduction of artemisinin-based combination therapy in Yaoundé, Cameroon: implications for the future.

Menard S, Morlais I, Tahar R, Sayang C, Mayengue PI, Iriart X, Benoit-Vical F, Lemen B, Magnaval JF, Awono-Ambene P, Basco LK, Berry A.

Malar J. 2012 Apr 12;11:113. doi: 10.1186/1475-2875-11-113.

PMID: 22498364 [PubMed - indexed for MEDLINE]

52. How can natural products serve as a viable source of lead compounds for the development of new/novel anti-malarials?

Guantai E, Chibale K.

Malar J. 2011 Mar 15;10 Suppl 1:S2. doi: 10.1186/1475-2875-10-S1-S2.

PMID: 21411013 [PubMed - in process]

53. Malarial parasites vs. antimalarials: never-ending rumble in the jungle.

Mordmüller B, Kremsner PG.

Curr Mol Med. 2006 Mar;6(2):247-51. Review.

PMID: 16515514 [PubMed - indexed for MEDLINE]

54.Plasmodium falciparum resistance to anti-malarial drugs in Papua New Guinea: evaluation of a community-based approach for the molecular monitoring of resistance.

Marfurt J, Smith TA, Hastings IM, Müller I, Sie A, Oa O, Baisor M, Reeder JC, Beck HP, Genton B.

Malar J. 2010 Jan 7;9:8. doi: 10.1186/1475-2875-9-8.

PMID: 20053293 [PubMed - indexed for MEDLINE]

55. A new double-antibody sandwich ELISA targeting Plasmodium falciparum aldolase to evaluate anti-malarial drug sensitivity.

Tritten L, Matile H, Brun R, Wittlin S.

Malar J. 2009 Oct 12;8:226. doi: 10.1186/1475-2875-8-226.

PMID: 19821995 [PubMed - indexed for MEDLINE]

56. New antibiotics for infections caused by resistant organisms.

McKinnon PS, Tam VH.

Support Care Cancer. 2001 Jan;9(1):8-10.

PMID: 11147147 [PubMed - indexed for MEDLINE]

57. Poor quality vital anti-malarials in Africa - an urgent neglected public health priority.

Newton PN, Green MD, Mildenhall DC, Plançon A, Nettey H, Nyadong L, Hostetler DM, Swamidoss I, Harris GA, Powell K, Timmermans AE, Amin AA, Opuni SK, Barbereau S, Faurant C, Soong RC, Faure K, Thevanayagam J, Fernandes P, Kaur H, Angus B, Stepniewska K, Guerin PJ, Fernández FM.

Malar J. 2011 Dec 13;10:352. doi: 10.1186/1475-2875-10-352.

PMID: 22152094[PubMed - indexed for MEDLINE]

58.Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID: 17993229 [PubMed - indexed for MEDLINE]

59. Current issues for anti-malarial drugs to control P. falciparum malaria.

Schellenberg D, Abdulla S, Roper C.

Curr Mol Med. 2006 Mar;6(2):253-60. Review.

PMID:16515515 [PubMed - indexed for MEDLINE]

60. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration.

Blondeau JM, Hansen G, Metzler K, Hedlin P.

J Chemother. 2004 Jun;16 Suppl 3:1-19. Review.

PMID: 15334827 [PubMed - indexed for MEDLINE]

61. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.

Caponigro F, Basile M, de Rosa V, Normanno N.

Anticancer Drugs. 2005 Feb;16(2):211-21.

PMID: 15655420 [PubMed - indexed for MEDLINE]

62. Variations in frequencies of drug resistance in Plasmodium falciparum.

Rathod PK, McErlean T, Lee PC.

Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9389-93.

PMID: 9256492 [PubMed - indexed for MEDLINE]

63. New trifluoromethyl triazolopyrimidines as anti-Plasmodium falciparum agents.

Boechat N, Pinheiro LC, Silva TS, Aguiar AC, Carvalho AS, Bastos MM, Costa CC, Pinheiro S, Pinto AC, Mendonça JS, Dutra KD, Valverde AL, Santos-Filho OA, Ceravolo IP, Krettli AU.

Molecules. 2012 Jul 10;17(7):8285-302. doi: 10.3390/molecules17078285.

PMID: 22781441 [PubMed - indexed for MEDLINE]

64. The emergence of antibiotic resistance: myths and facts in clinical practice.

Hamilton-Miller JM.

Intensive Care Med. 1990;16 Suppl 3:S206-11. Review.

PMID: 2289992 [PubMed - indexed for MEDLINE]

65. Localization of the ATP-binding cassette (ABC) transport proteins PfMRP1, PfMRP2, and PfMDR5 at the Plasmodium falciparum plasma membrane.

Kavishe RA, van den Heuvel JM, van de Vegte-Bolmer M, Luty AJ, Russel FG, Koenderink JB.

Malar J. 2009 Aug 28;8:205. doi: 10.1186/1475-2875-8-205.

PMID:19715599 [PubMed - indexed for MEDLINE]

66. The effect of mimicking febrile temperature and drug stress o­n malarial development.

Aunpad R, Somsri S, Na-Bangchang K, Udomsangpetch R, Mungthin M, Adisakwattana P, Chaijaroenkul W.

Ann Clin Microbiol Antimicrob. 2009 Jun 12;8:19. doi: 10.1186/1476-0711-8-19.

PMID:19523215 [PubMed - indexed for MEDLINE]

67. A natural product inspired hybrid approach towards the synthesis of novel pentamidine based scaffolds as potential anti-parasitic agents.

Tyagi V, Khan S, Shivahare R, Srivastava K, Gupta S, Kidwai S, Srivastava K, Puri SK, Chauhan PM.

Bioorg Med Chem Lett. 2013 Jan 1;23(1):291-6. doi: 10.1016/j.bmcl.2012.10.101. Epub 2012 Nov 1.

PMID: 23182089 [PubMed - in process]

68. Identification and activity of a series of azole-based compounds with lactate dehydrogenase-directed anti-malarial activity.

Cameron A, Read J, Tranter R, Winter VJ, Sessions RB, Brady RL, Vivas L, Easton A, Kendrick H, Croft SL, Barros D, Lavandera JL, Martin JJ, Risco F, García-Ochoa S, Gamo FJ, Sanz L, Leon L, Ruiz JR, Gabarró R, Mallo A, Gómez de las Heras F.

J Biol Chem. 2004 Jul 23;279(30):31429-39. Epub 2004 Apr 26.

PMID: 15117937 [PubMed - indexed for MEDLINE]

69. Development of resistance following the use of antibiotics.

Wiedemann B.

Scand J Gastroenterol Suppl. 1984;90:21-7.

PMID: 6588480 [PubMed - indexed for MEDLINE]

70. Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing.

Thybaud V, Aardema M, Clements J, Dearfield K, Galloway S, Hayashi M, Jacobson-Kram D, Kirkland D, MacGregor JT, Marzin D, Ohyama W, Schuler M, Suzuki H, Zeiger E; Expert Working Group o­n Hazard Identification and Risk Assessment in Relation to In Vitro Testing.

Mutat Res. 2007 Feb 3;627(1):41-58. Epub 2006 Nov 27.

PMID: 17126066 [PubMed - indexed for MEDLINE]

71. In vitro and in vivo assessment of the anti-malarial activity of Caesalpinia pluviosa.

Kayano AC, Lopes SC, Bueno FG, Cabral EC, Souza-Neiras WC, Yamauchi LM, Foglio MA, Eberlin MN, Mello JC, Costa FT.

Malar J. 2011 May 2;10:112. doi: 10.1186/1475-2875-10-112.

PMID:21535894 [PubMed - indexed for MEDLINE]

72.Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps.

Marrero-Ponce Y, Iyarreta-Veitía M, Montero-Torres A, Romero-Zaldivar C, Brandt CA, Avila PE, Kirchgatter K, Machado Y.

J Chem Inf Model. 2005 Jul-Aug;45(4):1082-100.

PMID: 16045304 [PubMed - indexed for MEDLINE]

73. Molecular markers of anti-malarial drug resistance in Lahj Governorate, Yemen: baseline data and implications.

Mubjer RA, Adeel AA, Chance ML, Hassan AA.

Malar J. 2011 Aug 21;10:245. doi: 10.1186/1475-2875-10-245.

PMID: 21854642[PubMed - indexed for MEDLINE]

74. Transgenic Plasmodium parasites stably expressing Plasmodium vivax dihydrofolate reductase-thymidylate synthase as in vitro and in vivo models for antifolate screening.

Somsak V, Uthaipibull C, Prommana P, Srichairatanakool S, Yuthavong Y, Kamchonwongpaisan S.

Malar J. 2011 Oct 7;10:291. doi: 10.1186/1475-2875-10-291.

PMID: 21981896 [PubMed - indexed for MEDLINE]

75. Pfatp6 molecular profile of Plasmodium falciparum isolates in the western Brazilian Amazon.

Brasil LW, Areas AL, Melo GC, Oliveira CM, Alecrim MG, Lacerda MV, O'Brien C, Oelemann WM, Zalis MG.

Malar J. 2012 Apr 10;11:111. doi: 10.1186/1475-2875-11-111.

PMID: 22487143 [PubMed - indexed for MEDLINE]

76. The prevalence and degree of resistance of Plasmodium falciparum to first-line antimalarial drugs: an in vitro study from a malaria endemic region in Yemen.

Al-Shamahy H, Al-Harazy AH, Harmal NS, Al-Kabsi AM.

Ann Saudi Med. 2007 Nov-Dec;27(6):432-6.

PMID: 18059124 [PubMed - indexed for MEDLINE]

77. Parallel synthesis of 9-aminoacridines and their evaluation against chloroquine-resistant Plasmodium falciparum.

Anderson MO, Sherrill J, Madrid PB, Liou AP, Weisman JL, DeRisi JL, Guy RK.

Bioorg Med Chem. 2006 Jan 15;14(2):334-43. Epub 2005 Oct 10.

PMID: 6216519 [PubMed - indexed for MEDLINE]

78.Parameters of acquired resistance and their role in the evaluation of new chemotherapeutic drugs.

Drews J.

Infection. 1976;4(2):61-9. Review.

PMID: 780282 [PubMed - indexed for MEDLINE]

79. The best of times, the worst of times. The global challenge of antimicrobial resistance.

Tenover FC.

Pharm World Sci. 1995 Sep 22;17(5):149-51. Review.

PMID: 8574209[PubMed - indexed for MEDLINE]

80. Potential contribution of prescription practices to the emergence and spread of chloroquine resistance in south-west Nigeria: caution in the use of artemisinin combination therapy.

Gbotosho GO, Happi CT, Ganiyu A, Ogundahunsi OA, Sowunmi A, Oduola AM.

Malar J. 2009 Dec 30;8:313. doi: 10.1186/1475-2875-8-313.

PMID: 20042098 [PubMed - indexed for MEDLINE]

Antimalarial compounds: from bench to bedside.

Olliaro PL, Taylor WR.

J Exp Biol. 2003 Nov;206(Pt 21):3753-9. Review.

PMID: 14506210 [PubMed - indexed for MEDLINE]

82. Detection of artemisinin-resistant Plasmodium falciparum in malarial infection: a brief review of methods.

Quashie NB.

J Trop Pediatr. 2010 Apr;56(2):119-21. doi: 10.1093/tropej/fmp074. Epub 2009 Aug 5. Review.

PMID: 19656841 [PubMed - indexed for MEDLINE]

83. A faster, high resolution, mtPA-GFP-based mitochondrial fusion assay acquiring kinetic data of multiple cells in parallel using confocal microscopy.

Lovy A, Molina AJ, Cerqueira FM, Trudeau K, Shirihai OS.

J Vis Exp. 2012 Jul 20;(65):e3991. doi: 10.3791/3991.

PMID:22847388 [PubMed - indexed for MEDLINE]

84.Anti-malarial drug formulations and novel delivery systems: a review.

Murambiwa P, Masola B, Govender T, Mukaratirwa S, Musabayane CT.

Acta Trop. 2011 May;118(2):71-9. doi: 10.1016/j.actatropica.2011.03.005. Epub 2011 Mar 31. Review.

PMID:21439929 [PubMed - indexed for MEDLINE]

85.Antiviral resistance and impact o­n viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases.

Nijhuis M, van Maarseveen NM, Boucher CA.

Handb Exp Pharmacol. 2009;(189):299-320. doi: 10.1007/978-3-540-79086-0_11. Review.

PMID: 19048205 [PubMed - indexed for MEDLINE]

86.[Malaria: from genetic and molecular biology to disease control].

Ambroise-Thomas P.

J Soc Biol. 2004;198(3):181-5. Review. French.

PMID: 15662933 [PubMed - indexed for MEDLINE]

87. Synthesis and exploration of novel curcumin analogues as anti-malarial agents.

Mishra S, Karmodiya K, Surolia N, Surolia A.

Bioorg Med Chem. 2008 Mar 15;16(6):2894-902. doi: 10.1016/j.bmc.2007.12.054. Epub 2008 Jan 1.

PMID: 18194869 [PubMed - indexed for MEDLINE]

88. A plant-derived morphinan as a novel lead compound active against malaria liver stages.

Carraz M, Jossang A, Franetich JF, Siau A, Ciceron L, Hannoun L, Sauerwein R, Frappier F, Rasoanaivo P, Snounou G, Mazier D.

PLoS Med. 2006 Dec;3(12):e513.

PMID: 17194195 [PubMed - indexed for MEDLINE]

89. Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries.

O'Connell KA, Gatakaa H, Poyer S, Njogu J, Evance I, Munroe E, Solomon T, Goodman C, Hanson K, Zinsou C, Akulayi L, Raharinjatovo J, Arogundade E, Buyungo P, Mpasela F, Adjibabi CB, Agbango JA, Ramarosandratana BF, Coker B, Rubahika D, Hamainza B, Chapman S, Shewchuk T, Chavasse D.

Malar J. 2011 Oct 31;10:326. doi: 10.1186/1475-2875-10-326.

PMID: 22039838 [PubMed - indexed for MEDLINE]

90. Different mutation patterns of atovaquone resistance to Plasmodium falciparum in vitro and in vivo: rapid detection of codon 268 polymorphisms in the cytochrome b as potential in vivo resistance marker.

Schwöbel B, Alifrangis M, Salanti A, Jelinek T.

Malar J. 2003 Mar 19;2:5. Epub 2003 Mar 19.

PMID: 12665429 [PubMed - indexed for MEDLINE]

91. Current opinion o­n an emergence of drug resistant strains of Plasmodium falciparum through genetic alterations.

Kasturi K, Mallika DS, Amos SJ, Venkateshaiah P, Rao KS.

Bioinformation. 2012;8(22):1114-8. doi: 10.6026/97320630081114. Epub 2012 Nov 13.

PMID: 23251047 [PubMed]

92. The state of the art in anti-malarial drug discovery and development.

Burrows JN, Chibale K, Wells TN.

Curr Top Med Chem. 2011;11(10):1226-54. Review.

PMID: 21401508 [PubMed - indexed for MEDLINE]

93. Malarial protease inhibitors: potential new chemotherapeutic agents.

Sharma A.

Curr Opin Investig Drugs. 2007 Aug;8(8):642-52. Review.

PMID: 17668366 [PubMed - indexed for MEDLINE]

94. Epidemiology of the emergence and spread of drug-resistant falciparum malaria in South-East Asia and Australasia.

Verdrager J.

J Trop Med Hyg. 1986 Dec;89(6):277-89.

PMID: 3543384 [PubMed - indexed for MEDLINE]

95. Reversal of chloroquine resistance in falciparum malaria.

Ryall JC.

Parasitol Today. 1987 Aug;3(8):256.

PMID: 15462975 [PubMed]

96. Chloroquine resistance in the malarial parasite, Plasmodium falciparum.

Ursos LM, Roepe PD.

Med Res Rev. 2002 Sep;22(5):465-91. Review.

PMID: 12210555 [PubMed - indexed for MEDLINE]

97. Anti-malarial drugs: how effective are they against Plasmodium falciparum gametocytes?

Peatey CL, Leroy D, Gardiner DL, Trenholme KR.

Malar J. 2012 Feb 6;11:34. doi: 10.1186/1475-2875-11-34.

PMID: 22305482 [PubMed - indexed for MEDLINE]

98. Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy.

Phillips MA, Rathod PK.

Infect Disord Drug Targets. 2010 Jun;10(3):226-39. Review.

PMID: 20334617 [PubMed - indexed for MEDLINE]

99. Transporters as mediators of drug resistance in Plasmodium falciparum.

Sanchez CP, Dave A, Stein WD, Lanzer M.

Int J Parasitol. 2010 Aug 15;40(10):1109-18. doi: 10.1016/j.ijpara.2010.04.001. Epub 2010 Apr 24. Review.

PMID: 20399785 [PubMed - indexed for MEDLINE]

 

Ngày 30/01/2013
PGS.TS. Triệu Nguyên Trung, TS. Nguyễn Văn Chương,
Ths.BS. Huỳnh Hồng Quang
 

THÔNG BÁO

   Dịch vụ khám chữa bệnh chuyên khoa của Viện Sốt rét-KST-CT Quy Nhơn khám bệnh tất cả các ngày trong tuần (kể cả thứ 7 và chủ nhật)

   THÔNG BÁO: Phòng khám chuyên khoa Viện Sốt rét-KST-CT Quy Nhơn xin trân trọng thông báo thời gian mở cửa hoạt động trở lại vào ngày 20/10/2021.


 LOẠI HÌNH DỊCH VỤ
 CHUYÊN ĐỀ
 PHẦN MỀM LIÊN KẾT
 CÁC VẤN ĐỀ QUAN TÂM
 QUẢNG CÁO

Trang tin điện tử Viện Sốt rét - Ký Sinh trùng - Côn trùng Quy Nhơn
Giấy phép thiết lập số 53/GP - BC do Bộ văn hóa thông tin cấp ngày 24/4/2005
Địa chỉ: Khu vực 8-Phường Nhơn Phú-Thành phố Quy Nhơn-Tỉnh Bình Định.
Tel: (84) 0256.3846.892 - Fax: (84) 0256.3647464
Email: impequynhon.org.vn@gmail.com
Trưởng Ban biên tập: TTND.PGS.TS. Hồ Văn Hoàng-Viện trưởng
Phó Trưởng ban biên tập: TS.BS.Huỳnh Hồng Quang-Phó Viện trưởng
• Thiết kế bởi công ty cổ phần phần mềm: Quảng Ích